BMS Continues Immuno-Oncology Push via Deals with CytomX and Incyte

Abstract

Continuing the high level of deal-making activity seen in the immuno-oncology sector thus far in 2014, Bristol-Myers Squibb (BMS) has formed separate deals with CytomX Therapeutics and Incyte. The deal with CytomX is focused on the discovery, development and commercialisation of masked antibody Probody™ therapies against up to four cancer targets. BMS will also collaborate with Incyte to evaluate its programmed cell death-1 (PD-1) inhibitor nivolumab in combination with Incyte’s INCB24360 in a Phase I/II trial.